These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose https://janejudt232351.izrablog.com/39519958/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide